|
|
|
Issue Open Date
|
11-Dec-24
|
|
|
|
Issue Closing Date
|
13-Dec-24
|
|
|
|
Application Money
|
100
|
|
|
|
Allotment Money
|
|
|
|
|
|
|
|
Price Band
|
522
-
549
|
|
|
|
Minimium Application No.
|
27
|
|
|
|
Issue Size (Shares)
|
38829848
|
|
|
|
Market Lot
|
1
|
|
|
|
|
|
Objective
|
|
1. Repayment/prepayment, in full or part, of all or certain outstanding borrowings availed by our Company; and2. General corporate purposes.
|
|
|
|
|
|
|
Category
|
No. of Shares
|
No. of Shares
|
Subscription Ratio
|
|
|
Offered / Reserved |
Bid For |
|
|
Non-Institutional Investors
|
8447426
|
41522058
|
4.9153503090764
|
|
Qualified Institutional Buyers
|
10671763
|
330125058
|
30.9344442900391
|
|
Retail Individual Investors
|
19710659
|
26912412
|
1.36537352708502
|
|
|
|
|
Business Description
We are an innovator-focused, contract research, development, and manufacturing organization (“CRDMO”). We provide end-to-end services across the drug discovery, development, and manufacturing value chain, for small molecule new chemical entities (“NCE”), to global pharmaceutical innovator companies and biotechnology firms. We possess both (a) discovery / contract research (“CRO”) and (b) chemistry, manufacturing, and control (“CMC”) / contract development and manufacturing organization (“CDMO”) capabilities. We are the fastest-growing Indian CRDMOs among listed Indian peers in terms of revenue CAGR as well as EBITDA CAGR from Financial Year 2022 to Financial Year 2024. (Source: F&S Report) Our CRDMO platform provides multiple entry points for us to acquire customers in the intermediate stages of their new drug discovery to commercialization journey. We are also one of the few CRDMOs to have a unique delivery model of having research laboratories for discovery and development located near overseas innovation hubs at Watertown (Greater Boston, MA), United States (“US”) and Manchester, United Kingdom (“UK”), complemented by large-scale research laboratories and manufacturing facilities in cost competitive locations in India. (Source: F&S Report) During the Financial Year 2024, we served more than 280 innovator pharmaceutical companies, including 18 of the top 25 pharmaceutical companies (in terms of revenue for the calendar year 2023), across regulated markets, including the US, the UK, Europe and Japan. (Source: F&S Report) During the Financial Year 2024, we also provided CRO services to more than 60 customers on an ongoing basis, for their integrated drug discovery programs. As of March 31, 2024, our CDMO product portfolio included more than 150 innovator pharmaceutical products, including 38 products that were supplied for manufacturing of 28 commercial drugs.
|
|
|
Promoter's Holding
|
|
|
|
Total Share Capital
|
77704340
|
|
|
|
Offered to Public
|
38829848
|
|
|
|
Promoter's Holding (Pre-Issue)
|
40.48
|
|
|
|
Promoter's Holding (Post-Issue)
|
35.24
|
|
|
|
|
|
|
|
|
|
|
Address |
Plot No. D S-7
I K P Knowledge Park
Turkapally Village
Shameerpet Mandal
Medchal- Malkajgiri District
Hyderabad,
Telangana,
500078
Phone : 040-68156000
Email : investors@sailife.com
Website : www.sailife.com
|
|
|
Registrar |
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B
Plot 31-32
Gachibowli
Financial District
Nanakramguda
Hyderabad
|
|
|
Listed at |
|
BSE, NSE
|
|
|
Lead Manager |
IIFL Securities Ltd.
Jefferies India Pvt Ltd.
Kotak Mahindra Capital Co Ltd
Morgan Stanley India Co Pvt Ltd
|
|
|
Promoters |
Kanumuri Mytreyi
Kanumuri Ranga Raju
Krishnam Raju Kanumuri
Marigold Partners
Sai Quest Syn Pvt Ltd.
Sunflower Partners
Tulip Partners and Lily Partners
|
|
